Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Key Stats

• Today's Range: $0.52 to $0.58
• 50-Day Range: $0.41 to $0.67
• 52-Week Range: $0.38 to $8.98
• Volume: 3.89 million shs
• Average Volume: 600,296 shs
• Market Capitalization: $48.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Verrica Pharmaceuticals Stock Analysis - MarketRank™

Verrica Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 206th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Verrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Verrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verrica Pharmaceuticals is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verrica Pharmaceuticals is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.98% of the float of Verrica Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Verrica Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verrica Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Verrica Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

6.98% of the float of Verrica Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Verrica Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Verrica Pharmaceuticals has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for VRCA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VRCA Stock Analysis - Frequently Asked Questions

How have VRCA shares performed this year?

Verrica Pharmaceuticals' stock was trading at $0.70 at the beginning of the year. Since then, VRCA shares have decreased by 25.3% and is now trading at $0.5226.
View the best growth stocks for 2025 here.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. The business had revenue of $3.44 million for the quarter, compared to analysts' expectations of $2.53 million.
Read the conference call transcript.

When did Verrica Pharmaceuticals IPO?

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Who are Verrica Pharmaceuticals' major shareholders?

Top institutional shareholders of Verrica Pharmaceuticals include Armistice Capital LLC (9.27%), Goldman Sachs Group Inc. (0.15%), Goldman Sachs Group Inc. (0.15%) and Kovitz Investment Group Partners LLC (0.11%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Ted White, Christopher G Hayes and Joe Bonaccorso.
View institutional ownership trends.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/28/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRCA
• CIK: 1660334
• Web: www.verrica.com
• Phone: (434) 453-3300
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +1,430.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$76.58 million
• Net Margins: N/A
• Pretax Margin: -919.21%
• Return on Equity: N/A
• Return on Assets: -145.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $7.57 million
• Price / Sales: 6.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.11) per share
• Price / Book: -4.75

Miscellaneous

• Outstanding Shares: 92,490,000
• Free Float: 42,546,000
• Market Cap: $48.34 million
• Optionable: Optionable
• Beta: 1.75